• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    4/30/25 4:30:25 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXI alert in real time by email
    false 0001644963 0001644963 2025-04-24 2025-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): April 24, 2025

     

    Avenue Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware
    (State or Other Jurisdiction
    of Incorporation)

    001-38114
    (Commission File Number)

     

    47-4113275
    (IRS Employer Identification No.)

     

     

    1111 Kane Concourse, Suite 301

    Bay Harbor Islands, Florida 33154

    (Address of Principal Executive Offices)

     

    (781) 652-4500

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act.
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Class Trading Symbol(s) Exchange Name
    Common Stock ATXI Nasdaq Capital Market(1)

     

    (1)On March 17, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that Nasdaq had determined to delist the Company’s common stock and that trading of the Company’s securities would be suspended at the open of trading on March 19, 2025. Nasdaq will file a Form 25 with the SEC notifying the SEC of Nasdaq’s determination to remove the Company’s securities from listing on Nasdaq, at which time the common stock will cease to be registered pursuant to Section 12(b) of the Act and immediately be deemed registered pursuant to Section 12(g) of the Act. Since March 19, 2025, the Company’s common stock has been traded on the over-the-counter market under the symbol “ATXI”.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    As previously disclosed, on February 28, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) entered into a license agreement (the “License Agreement”) with AnnJi Pharmaceutical Co., Ltd., a Taiwanese company (“AnnJi”), pursuant to which the Company obtained an exclusive license from AnnJi to intellectual property rights pertaining to the molecule known as JM17, which activates Nrf1 and Nrf2, enhances androgen receptor degradation and underlies AJ201, a clinical product candidate currently in a Phase 1b/2a clinical trial in the U.S. for the treatment of spinal and bulbar muscular atrophy, also known as Kennedy’s Disease. As also previously disclosed, on March 3, 2025, the Company received a notice of AnnJi’s intent to terminate the License Agreement, in which AnnJi asserted several bases for its right to terminate the License Agreement.

     

    On April 24, 2025 (the “Effective Date”), the Company and AnnJi entered into a License Termination and Program Transfer Agreement (the “Termination and Transfer Agreement”), pursuant to which: (i) the License Agreement (as well as the Subscription Agreement and the Registration Rights Agreement entered into in connection therewith) was terminated with immediate effect; (ii) the parties dismissed all pending dispute resolution proceedings and provided mutual releases of claims; (iii) Avenue transferred to AnnJi all of its rights, title and interest to and under the assets arising under the License Agreement and otherwise related to AJ201 and (iv) Avenue agreed not to, for 48 months following the date of the Termination and Transfer Agreement, develop, commercialize, manufacture or sell any product competing with AJ201 in the US, Canada, the European Union, Great Britain or Israel. Under the Termination and Transfer Agreement, the Company will repurchase, for an aggregate payment of $1.00, all 14,777 shares of Avenue common stock that are held by AnnJi, and the Company also made a payment of $0.2 million to AnnJi as consideration for legal expenses.

     

    AnnJi agreed to make payments to Avenue of $2.0 million in the aggregate over the next 90 days, with $1.0 million due within 30 days after the Effective Date and $1 million due within 90 days after the Effective Date. Additionally, Avenue will be eligible to receive from AnnJi:

     

    ·payments totaling up to $5 million in the aggregate upon the occurrence of certain development and regulatory milestone events pertaining to AJ201;
    ·payments totaling up to $17 million in the aggregate upon AJ201 experiencing certain commercial sales milestone events;
    ·a 1.75% royalty on net sales of AJ201, which royalty percentage is subject to potential diminution in certain circumstances; and
    ·in the event that AnnJi enters into one or more subsequent licenses of rights to AJ201 with third party licensee(s), 15% of payments received by AnnJi from such licensee(s), up to a cap of $7.5 million, and with a minimum of $4 million owing under certain mechanism in the event of an approval of a New Drug Application in the U.S. with respect to AJ201.

     

    The Termination and Transfer Agreement also contains customary representations and warranties and provisions related to confidentiality and indemnification. The foregoing summary of the material terms of the Termination and Transfer Agreement is qualified in its entirety by the complete terms and conditions of the Termination and Transfer Agreement, which is being filed with the Securities and Exchange Commission concurrently herewith.

     

    Item 1.02 Termination of a Material Definitive Agreement.

     

    The disclosures set forth in Item 1.01 are incorporated by reference herein.

     

    Item 2.01 Completion of Acquisition or Disposition of Assets.

     

    The disclosures set forth in Item 1.01 are incorporated by reference herein.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are furnished herewith:

     

    Exhibit
    Number
      Description
    10.1   AnnJi License Termination and Program Transfer Agreement by and between the Company and AnnJi Pharmaceutical Co., Ltd., dated April 24, 2025.*  
    104   Cover Page Interactive Data File (embedded within Inline XBRL document)

     

    *  Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AVENUE THERAPEUTICS, INC.
      (Registrant)
    Date: April 30, 2025    
      By: /s/ David Jin
        David Jin
        Interim Principal Financial Officer and Chief Operating Officer

     

     

     

    Get the next $ATXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATXI
    Financials

    Live finance-specific insights

    See more
    • Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

      MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

      3/25/24 8:30:00 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

      Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

      8/14/23 4:01:50 PM ET
      $ATXI
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    SEC Filings

    See more
    • Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

      4/30/25 4:30:25 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.

      SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      4/2/25 5:00:06 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Avenue Therapeutics Inc.

      10-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

      3/31/25 4:16:02 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

      MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. "We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet m

      11/14/24 4:05:03 PM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

      MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here. About Avenue TherapeuticsAvenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focus

      10/9/24 8:30:59 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avenue Therapeutics to Participate in Upcoming Investor Conferences

      MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright

      9/3/24 8:30:35 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      10/1/24 4:15:13 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      4/2/25 4:05:13 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Fortress Biotech, Inc. claimed ownership of 294,800 shares (SEC Form 3)

      3 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      1/3/25 4:21:27 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Herskowitz Neil sold $46 worth of shares (23 units at $2.00), decreasing direct ownership by 19% to 97 units (SEC Form 4)

      4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

      12/3/24 4:30:17 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Leadership Updates

    Live Leadership Updates

    See more
    • Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

      MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar

      10/3/22 8:00:00 AM ET
      $ATXI
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

      SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      11/15/24 4:05:50 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avenue Therapeutics Inc.

      SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      11/14/24 3:22:45 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Avenue Therapeutics Inc. (Amendment)

      SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

      5/2/24 4:02:02 PM ET
      $ATXI
      Biotechnology: Pharmaceutical Preparations
      Health Care